Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$51.76 USD
-0.04 (-0.08%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $51.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 61 - 80 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Leading Rare Disease Developer Trading at a Steep Discount Heading Into a Catalyst-Rich 2023; Assume Buy, $82 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Commercial Biotech Preview: Regulatory Catalysts Likely The Main Event
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Commercial Execution Remains Solid for RARE in 2Q22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
RARE Buys an Angel(man drug) - Updated GTX-102 Data Arrives
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Creative Financing On Display With Crysvita, OMERS Transaction
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department